Pharmacogenomics: Social, Ethical, and Clinical Dimensions

In this remarkably broad and far–reaching work, editor Mark Rothstein and his distinguished list of contributors have laid out an impressive framework for the field. Beginning with a survey of public attitudes, and progressing through scientific, clinical, governmental, legal, economic, and societal issues, the text builds to a final provocative epilogue on consequences for public policy."
–from the Foreword by Francis S. Collins
Pharmacogenomics promises to revolutionize medicine by enabling the prevention, diagnosis, and treatment of diseases at the genome level. While a substantial amount of public and private research focuses on new pharmacogenomic applications, notably less attention has been directed to the ethical, legal, and social implications of "individualized medicine." Mark Rothstein′s timely anthology reduces that scholarship deficit, presenting a multidisciplinary analysis of the scientific, clinical, economic, ethical, social, and legal implications of pharmacogenomics.
Assembling an all–star cast of bioethical scholars, medical researchers, legal scholars, and social scientists, Mark Rothstein examines the promises, questions, and concerns these revolutionary therapies implicitly present. Among other features, Pharmacogenomics:
∗ Reports for the first time the results of the first detailed, national survey of public attitudes regarding pharmacogenomics
∗ Covers informed consent, privacy, confidentiality, and risk–benefit evaluations
∗ Analyzes the potentially enormous changes in the standard of care and the approach to treatment with the development and application of pharmacogenomic technology
∗ Addresses practical considerations of education, training, oversight, guidelines and protocols, and continuing education requirements
∗ Recommends approaches to respond to the more complex issues of safety, efficacy, and quality in the distribution and development of indiv idualized therapies
∗ Explores the new legal standards and implementation challenges
∗ Offers a policy framework that balances the benefits and risks and considers the wide range of legislative, regulatory, and professional options
Biotechnology and pharmaceutical researchers and regulators, health care professionals and students, and academics and policymakers will find Pharmacogenomics to be a valuable resource.

Spis treści:
Foreword (F. Collins).
Preface.
PART I: INTRODUCTION: SCIENCE AND SOCIETY.
Public Attitudes About Pharmacogenomics (M. Rothstein, et al.).
Pharmacogenomics:  Pharmacology and Toxicology in the Genomics (H. Mohrenweiser).
The Implications of Population Genetics for Pharmacogenomics (C. Hanis).
PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS.
Genome Research and Minorities (H. Greely).
Drug Development Strategies (P. Manasco & T. Arledge).
Drug Development,  Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman).
Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally,  et al.).
PART III: CLINICAL APPLICATIONS.
Integration of Pharmacogenomics into Medical Practice (G. Omenn & A. Motulsky).
Clinical Utility Pharmacogenetics and Pharmacogenomics (N. Holtzman).
Medical Liability for Pharmacogenomics (L. Palmer).
The Challenges of Pharmacogenomics for Pharmacy Education, Practice, and Regulation  (D. Brushwood).
PART IV: THE SOCIAL DIMENSION.
Economic Implications of Pharmacogenomics (C. Reeder & W. Dickson). 
 Pharmacogenomics and the Social Construction of Identity (M. Foster).
Pharmacogenomics: Considerations for Communities of Color (L. Nsiah–Jefferson).
Constitutional Issues in the Use of Pharmacogenomic Variations Associated with Race (J. Robertson).
PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein).
Pharmacogenomics and Minority Populations: General Population Survey Questionnaire (M. Rothstein).
Index.

Okładka tylna:
"In this remarkably broad and far–reaching work, editor Mark Rothstein and his distinguished list of contributors have laid out an impressive framework for the field. Beginning with a survey of public attitudes, and progressing through scientific, clinical, governmental, legal, economic, and societal issues, the text builds to a final provocative epilogue on consequences for public policy."
–from the Foreword by Francis S. Collins
Pharmacogenomics promises to revolutionize medicine by enabling the prevention, diagnosis, and treatment of diseases at the genome level. While a substantial amount of public and private research focuses on new pharmacogenomic applications, notably less attention has been directed to the ethical, legal, and social implications of "individualized medicine." Mark Rothstein′s timely anthology reduces that scholarship deficit, presenting a multidisciplinary analysis of the scientific, clinical, economic, ethical, social, and legal implications of pharmacogenomics.
Assembling an all–star cast of bioethical scholars, medical researchers, legal scholars, and social scientists, Mark Rothstein examines the promises, questions, and concerns these revolutionary therapies implicitly present. Among other features, Pharmacogenomics:
∗ Reports for the first time the results of the first detailed, national survey of public attitudes regarding pharmacogenomics
∗ Covers informed consent, privacy, confidentiality, and risk–benefit evaluations
∗ Analyzes the potentially enormous changes in the standard of care and the approach to treatment with the development and application of pharmacogenomic technology
∗ Addresses practical considerations of education, training, oversight, guidelines and protocols, and continuing education requirements
∗ Recommends approaches to respond to the more complex issues of safety, efficacy, and quality in the distribution and development of individualized therapies
∗ Explores the new legal standards and implementation challenges
∗ Offers a policy framework that balances the benefits and risks and considers the wide range of legislative, regulatory, and professional options
Biotechnology and pharmaceutical researchers and regulators, health care professionals and students, and academics and policymakers will find Pharmacogenomics to be a valuable resource.